You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Meprobamate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for meprobamate and what is the scope of patent protection?

Meprobamate is the generic ingredient in nine branded drugs marketed by Medpointe Pharm Hlc, Wyeth Ayerst, Ferndale Labs, Alra, Teva, Acella, Alembic Pharms Ltd, Barr, Chartwell Molecular, Elkins Sinn, Heather, Impax Labs, Invagen Pharms, Ivax Sub Teva Pharms, Lederle, Lee Km, Mallard, Mk Labs, Mylan, Nexgen Pharma Inc, Parke Davis, Perrigo, Pharmavite, Purepac Pharm, Pvt Form, Rising, Roxane, Sandoz, Scherer Labs, Solvay, Stanlabs Pharm, Sun Pharm Industries, Tablicaps, Taro, Usl Pharma, Valeant Pharm Intl, Vangard, Watson Labs, West Ward, Whiteworth Town Plsn, and Halsey, and is included in fifty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for meprobamate. Four suppliers are listed for this compound.

Summary for meprobamate
Drug Prices for meprobamate

See drug prices for meprobamate

Medical Subject Heading (MeSH) Categories for meprobamate
Anatomical Therapeutic Chemical (ATC) Classes for meprobamate

US Patents and Regulatory Information for meprobamate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chartwell Molecular MEPROBAMATE meprobamate TABLET;ORAL 014882-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Medpointe Pharm Hlc MILTOWN meprobamate TABLET;ORAL 009698-004 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Watson Labs MEPROBAMATE meprobamate TABLET;ORAL 084274-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Whiteworth Town Plsn MEPROBAMATE meprobamate TABLET;ORAL 083830-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Chartwell Molecular MEPROBAMATE meprobamate TABLET;ORAL 014882-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Ferndale Labs AMOSENE meprobamate TABLET;ORAL 084030-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Impax Labs MEPROBAMATE meprobamate TABLET;ORAL 014322-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Meprobamate Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Meprobamate

Introduction

Meprobamate, a medication with sedative and anxiolytic properties, has been a part of the pharmaceutical landscape for several decades. Understanding its market dynamics and financial trajectory is crucial for stakeholders, including pharmaceutical companies, investors, and healthcare providers.

Market Overview

Global and Regional Markets

The meprobamate market is influenced by various regional factors, including healthcare policies, demand for anxiolytic and muscle relaxant medications, and the availability of alternative treatments.

  • Qatar Market: In Qatar, the meprobamate market is expected to experience moderate growth driven by the development of the country's healthcare infrastructure and increasing awareness of mental health issues. However, the market faces challenges such as regulatory scrutiny and safety concerns due to meprobamate's classification as a controlled substance[1].
  • United States Market: In the United States, the meprobamate market is also anticipated to grow during the 2024-2030 period. This growth is attributed to the increasing demand for pharmaceuticals, particularly for anxiety and stress-related disorders[4].

Market Drivers

Several factors drive the demand for meprobamate:

Increasing Mental Health Awareness

The rising awareness of mental health issues and stress-related disorders is a significant driver. As more people seek medical help for anxiety and related conditions, the demand for meprobamate and other anxiolytic medications is likely to increase[1][4].

Healthcare Infrastructure Development

The development and expansion of healthcare infrastructure in regions like Qatar contribute to the growing demand for pharmaceuticals, including meprobamate. Improved healthcare facilities and increased access to medical services enhance the market's potential[1].

Pandemic Impact

The COVID-19 pandemic has had a mixed impact on the pharmaceutical sector. While it increased the demand for certain medications due to heightened stress and anxiety levels, it also caused supply chain disruptions that may have led to temporary shortages of meprobamate[1].

Market Restraints

Despite the drivers, several restraints affect the meprobamate market:

Regulatory Scrutiny

Meprobamate's classification as a controlled substance due to its sedative properties imposes strict regulations on its production, distribution, and usage. This regulatory environment poses significant challenges for companies, making it difficult to navigate the legal framework while ensuring profitability[1].

Safety Concerns

Safety concerns associated with meprobamate, such as its potential for abuse and side effects, can limit its market growth. These concerns often lead to stricter prescribing practices and increased scrutiny from regulatory bodies[1].

Alternative Medications

The rising demand for alternative medications and treatments for anxiety and related disorders further complicates the outlook for the meprobamate market. Patients and healthcare providers may prefer newer, safer, or more effective treatments, reducing the demand for meprobamate[1].

Market Trends

Competitive Landscape

The pharmaceutical industry, including the meprobamate market, is highly competitive. Key players such as Pfizer, Novartis, and Johnson & Johnson dominate the market. Companies must innovate and find new avenues for product development and market expansion to remain competitive[1][4].

Collusion and Price Manipulation

There have been instances of collusion in the generic drug industry, including meprobamate. Studies have shown that such collusive behavior can significantly increase prices. For example, a study found that the price of meprobamate increased by $7.57 per defined daily dose during a cartel period, representing a 166% increase[3].

Financial Trajectory

Revenue and Volume Projections

  • Qatar Market: The meprobamate market in Qatar is expected to see moderate growth in revenues and volume from 2020 to 2030. The market revenues and volume share are projected to increase, driven by the growing healthcare needs of the population[1].
  • United States Market: In the United States, the meprobamate market is projected to grow during the 2024-2030 period, with increasing revenues and volume share across various applications, including pharmaceuticals and consumer goods[4].

Import-Export Trade Statistics

The import and export trade statistics for meprobamate reveal that the market is influenced by international trade. Companies must navigate import and export regulations and ensure compliance to maintain a stable supply chain[1][4].

Key Performance Indicators

Key performance indicators such as market revenues, volume share, and import-export statistics are crucial for assessing the financial health of the meprobamate market. These indicators help companies and investors make informed decisions about market entry, expansion, and investment strategies[1][4].

Opportunity Assessment

By Application

The meprobamate market presents opportunities across various applications, including pharmaceuticals, agriculture, chemicals, and consumer goods. Companies can explore these segments to diversify their product offerings and expand their market share[1][4].

Addressing Regulatory Hurdles

To capitalize on market opportunities, companies must address the regulatory hurdles associated with meprobamate. This includes complying with strict regulations, ensuring safety standards, and innovating to stay ahead of competitors[1].

Competitive Landscape

The competitive landscape of the meprobamate market is characterized by the presence of major pharmaceutical companies. These companies compete on factors such as product quality, pricing, and regulatory compliance. The market revenue share is distributed among these key players, with a focus on innovation and market expansion[1][4].

Conclusion

The meprobamate market is influenced by a complex interplay of factors including healthcare policies, regulatory scrutiny, and the availability of alternative treatments. While the market faces challenges, it also presents opportunities for growth and expansion. Companies must navigate these dynamics carefully to ensure profitability and market dominance.

Key Takeaways

  • The meprobamate market is expected to grow moderately in regions like Qatar and the United States.
  • Regulatory scrutiny and safety concerns are significant challenges.
  • Increasing mental health awareness and healthcare infrastructure development are key drivers.
  • Alternative medications and collusion in the generic drug industry can impact market dynamics.
  • Companies must innovate and comply with regulations to remain competitive.

FAQs

What are the primary uses of meprobamate?

Meprobamate is primarily used as an anxiolytic and muscle relaxant in the pharmaceutical sector.

How does regulatory scrutiny affect the meprobamate market?

Regulatory scrutiny due to meprobamate's classification as a controlled substance imposes strict regulations on its production, distribution, and usage, making it challenging for companies to navigate the legal framework while ensuring profitability.

What impact did the COVID-19 pandemic have on the meprobamate market?

The pandemic increased the demand for certain medications due to heightened stress and anxiety levels but also caused supply chain disruptions that may have led to temporary shortages of meprobamate.

How does collusion in the generic drug industry affect meprobamate prices?

Collusion in the generic drug industry can significantly increase prices. For example, a study found that the price of meprobamate increased by $7.57 per defined daily dose during a cartel period, representing a 166% increase.

What are the key drivers of the meprobamate market?

Key drivers include increasing mental health awareness, development of healthcare infrastructure, and the ongoing demand for anxiolytic and muscle relaxant medications.

Sources

  1. 6Wresearch, "Qatar Meprobamate Market (2024-2030) | Trends, Outlook & Forecast"
  2. Journal of Clinical Sleep Medicine, "Clinical Guideline for the Evaluation and Management of Chronic Adult Insomnia"
  3. EconStor, "Collusion in the US generic drug industry"
  4. 6Wresearch, "United States (US) Meprobamate Market (2024-2030) Outlook"
  5. Colorado Department of Labor and Employment, "RULE 17, EXHIBIT 9 - Chronic Pain Disorder Medical Treatment Guidelines"

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.